Physician profile
David Mccoy
NPI 1477847416
$5,505.88
in general payments reported to CMS, 2019-2025
28 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,110 · 2020: $600 · 2021: $152 · 2022: $441 · 2023: $640 · 2024: $224 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.78 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,936.21 | 2019-2020 | |
| Abbott Laboratories | $912.01 | 2022-2024 | Infinity |
| Teva Pharmaceuticals USA, INC. | $618.71 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $257.98 | 2019-2022 | |
| Lundbeck LLC | $231.24 | 2019-2020 | |
| Tg Therapeutics, INC. | $224.76 | 2024-2025 | |
| Sk Life Science, INC. | $210.70 | 2020-2022 | |
| Ucb, INC. | $174.10 | 2019 | |
| Alexion Pharmaceuticals, INC. | $121.99 | 2019-2024 | Ultomiris |
| Allergan, INC. | $96.88 | 2019-2020 | |
| Livanova USA, INC. | $89.17 | 2019 | |
| Sumitomo Pharma America, INC. | $88.00 | 2023 | Aptiom |
| Amgen INC. | $86.03 | 2019-2022 | |
| Abbvie INC. | $77.76 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $69.25 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $59.23 | 2019 | |
| Eisai INC. | $46.48 | 2021-2025 | |
| Lilly USA, LLC | $45.10 | 2019 | |
| Acorda Therapeutics, INC | $26.61 | 2019 | |
| Argenx US, INC. | $21.08 | 2023 | Vyvgart |
| Genzyme Corporation | $19.14 | 2019 | |
| Neuronetics, INC. | $17.61 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.00 | 2021 | |
| Genentech USA, INC. | $12.21 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.14 | 2019 | |
| Biogen, INC. | $11.30 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.